From Yahoo Finance: 2025-06-02 05:23:00

Summit Therapeutics’ stock plunged over 30% due to disappointing ivonescimab clinical trial results. The bispecific antibody showed a reduction in tumor growth but lacked a convincing overall survival benefit. FDA approval for US sales is unlikely. Despite challenges, investors remain hopeful for future potential sales comparable to Keytruda’s success.

Read more: Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?